Susceptibility of helicobacter pylori to metronidazole and its bioactive derivatives

The hydroxy derivative of metronidazole can exhibit equal or greater activity to the parent drug against several bacteria. The susceptibility status of <i>22 H. pylori </i>strains to these breakdown compounds was determined in order to determine their possible role in the therapy of <...

Full description

Bibliographic Details
Main Author: Bannatyne Robert
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 1998-01-01
Series:The Saudi Journal of Gastroenterology
Online Access:http://www.saudijgastro.com/article.asp?issn=1319-3767;year=1998;volume=4;issue=3;spage=156;epage=158;aulast=Bannatyne
_version_ 1818050199188144128
author Bannatyne Robert
author_facet Bannatyne Robert
author_sort Bannatyne Robert
collection DOAJ
description The hydroxy derivative of metronidazole can exhibit equal or greater activity to the parent drug against several bacteria. The susceptibility status of <i>22 H. pylori </i>strains to these breakdown compounds was determined in order to determine their possible role in the therapy of <i>H. pylori </i>associated peptic ulcer disease. The susceptibility was determined using the agar dilution method and substantial activity (MIC90 = 0.33 .tg/ml) for the hydroxy metabolite of metronidazole versus <i>H. pylori </i>was observed. The findings define a role for the hydroxy derivative of metronidazole in peptic ulcer disease and support the limited data on the possibility of cooperative interactions between the parent compound, its main derivatives and related companion drugs in this condition.
first_indexed 2024-12-10T10:49:40Z
format Article
id doaj.art-27aef9dab9794cb581c6f2441413daa5
institution Directory Open Access Journal
issn 1319-3767
language English
last_indexed 2024-12-10T10:49:40Z
publishDate 1998-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series The Saudi Journal of Gastroenterology
spelling doaj.art-27aef9dab9794cb581c6f2441413daa52022-12-22T01:52:03ZengWolters Kluwer Medknow PublicationsThe Saudi Journal of Gastroenterology1319-37671998-01-0143156158Susceptibility of helicobacter pylori to metronidazole and its bioactive derivativesBannatyne RobertThe hydroxy derivative of metronidazole can exhibit equal or greater activity to the parent drug against several bacteria. The susceptibility status of <i>22 H. pylori </i>strains to these breakdown compounds was determined in order to determine their possible role in the therapy of <i>H. pylori </i>associated peptic ulcer disease. The susceptibility was determined using the agar dilution method and substantial activity (MIC90 = 0.33 .tg/ml) for the hydroxy metabolite of metronidazole versus <i>H. pylori </i>was observed. The findings define a role for the hydroxy derivative of metronidazole in peptic ulcer disease and support the limited data on the possibility of cooperative interactions between the parent compound, its main derivatives and related companion drugs in this condition.http://www.saudijgastro.com/article.asp?issn=1319-3767;year=1998;volume=4;issue=3;spage=156;epage=158;aulast=Bannatyne
spellingShingle Bannatyne Robert
Susceptibility of helicobacter pylori to metronidazole and its bioactive derivatives
The Saudi Journal of Gastroenterology
title Susceptibility of helicobacter pylori to metronidazole and its bioactive derivatives
title_full Susceptibility of helicobacter pylori to metronidazole and its bioactive derivatives
title_fullStr Susceptibility of helicobacter pylori to metronidazole and its bioactive derivatives
title_full_unstemmed Susceptibility of helicobacter pylori to metronidazole and its bioactive derivatives
title_short Susceptibility of helicobacter pylori to metronidazole and its bioactive derivatives
title_sort susceptibility of helicobacter pylori to metronidazole and its bioactive derivatives
url http://www.saudijgastro.com/article.asp?issn=1319-3767;year=1998;volume=4;issue=3;spage=156;epage=158;aulast=Bannatyne
work_keys_str_mv AT bannatynerobert susceptibilityofhelicobacterpyloritometronidazoleanditsbioactivederivatives